SQZ Biotech Announces Pricing of Initial Public Offering
October 29 2020 - 7:32PM
Business Wire
SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”) today announced
the pricing of its initial public offering of 4,411,765 shares of
common stock at a public offering price of $16.00 per share. All of
the shares of common stock are being offered by SQZ. In addition,
SQZ has granted the underwriters a 30-day option to purchase up to
an additional 661,764 shares of its common stock at the initial
public offering price, less the underwriting discounts and
commissions, to cover over-allotments, if any. SQZ’s common stock
is expected to begin trading on the New York Stock Exchange on
October 30, 2020 under the ticker symbol “SQZ.” The offering is
expected to close on November 3, 2020, subject to customary closing
conditions.
BofA Securities, Evercore ISI and Stifel are acting as joint
book-running managers for the offering. BTIG is acting as lead
manager for the offering.
A registration statement relating to the securities being sold
in the offering was declared effective by the Securities and
Exchange Commission on October 29, 2020. This offering is being
made only by means of a prospectus. Copies of the final prospectus
relating to this offering may be obtained, when available, by
contacting: BofA Securities, NC1-004-03-43, 200 North College
Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus
Department, or by email at dg.prospectus_requests@bofa.com;
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 35th Floor, New York, New York 10055, or by telephone
at (888) 474 0200, or by email at ecm.prospectus@evercore.com; or
Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate,
One Montgomery Street, Suite 3700, San Francisco, California 94104,
by telephone at 415-364-2720 or by email at
syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or
jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201029006375/en/
Media: Kate Contreras Associate Director
kcontreras@w2ogroup.com 617-229-5960 Investors: Rebecca
Cohen Corporate and Investor Relations rebecca.cohen@sqzbiotech.com
617-758-8672 ext. 728
Serica Energy (LSE:SQZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Serica Energy (LSE:SQZ)
Historical Stock Chart
From Apr 2023 to Apr 2024